Compare STRIDES PHARMA SCIENCE with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs SANOFI INDIA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE SANOFI INDIA STRIDES PHARMA SCIENCE/
SANOFI INDIA
 
P/E (TTM) x 43.6 40.0 108.9% View Chart
P/BV x 2.0 8.1 25.0% View Chart
Dividend Yield % 0.2 1.1 22.3%  

Financials

 STRIDES PHARMA SCIENCE   SANOFI INDIA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
SANOFI INDIA
Dec-18
STRIDES PHARMA SCIENCE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1476,840 16.8%   
Low Rs6424,630 13.9%   
Sales per share (Unadj.) Rs317.21,203.1 26.4%  
Earnings per share (Unadj.) Rs7.8165.3 4.7%  
Cash flow per share (Unadj.) Rs25.1209.9 11.9%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.21.5 15.3%  
Book value per share (Unadj.) Rs274.3963.6 28.5%  
Shares outstanding (eoy) m89.5023.03 388.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.8 59.1%   
Avg P/E ratio x114.034.7 328.6%  
P/CF ratio (eoy) x35.727.3 130.6%  
Price / Book Value ratio x3.36.0 54.8%  
Dividend payout %25.550.8 50.2%   
Avg Mkt Cap Rs m80,058132,078 60.6%   
No. of employees `0002.53.3 75.9%   
Total wages/salary Rs m4,3414,068 106.7%   
Avg. sales/employee Rs Th11,325.88,393.8 134.9%   
Avg. wages/employee Rs Th1,731.41,232.4 140.5%   
Avg. net profit/employee Rs Th280.11,153.0 24.3%   
INCOME DATA
Net Sales Rs m28,39427,708 102.5%  
Other income Rs m941897 104.9%   
Total revenues Rs m29,33428,605 102.5%   
Gross profit Rs m3,9656,235 63.6%  
Depreciation Rs m1,5401,027 150.0%   
Interest Rs m1,9627 28,034.3%   
Profit before tax Rs m1,4036,098 23.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,292 4.2%   
Profit after tax Rs m7023,806 18.4%  
Gross profit margin %14.022.5 62.1%  
Effective tax rate %6.937.6 18.4%   
Net profit margin %2.513.7 18.0%  
BALANCE SHEET DATA
Current assets Rs m24,83615,922 156.0%   
Current liabilities Rs m18,9936,235 304.6%   
Net working cap to sales %20.635.0 58.9%  
Current ratio x1.32.6 51.2%  
Inventory Days Days7164 111.5%  
Debtors Days Days11321 543.5%  
Net fixed assets Rs m34,2897,539 454.8%   
Share capital Rs m895230 389.1%   
"Free" reserves Rs m23,65121,962 107.7%   
Net worth Rs m24,54622,192 110.6%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43729,839 219.3%  
Interest coverage x1.7872.1 0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.9 46.7%   
Return on assets %4.112.8 31.9%  
Return on equity %2.917.2 16.7%  
Return on capital %6.927.5 25.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6977,587 206.9%   
Fx outflow Rs m7357,145 10.3%   
Net fx Rs m14,962442 3,385.0%   
CASH FLOW
From Operations Rs m1,8713,739 50.0%  
From Investments Rs m5,826-731 -797.0%  
From Financial Activity Rs m-10,157-1,972 515.1%  
Net Cashflow Rs m-2,6151,036 -252.4%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 37.8 14.4 262.5%  
FIIs % 8.6 14.6 58.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 15,184 370.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ALEMBIC PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Interglobe Aviation QIP, Rising Premium for Non-Life Insurers, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended lower yesterday. Benchmark indices ended nearly 1% lower, tracking weakness in global markets and dragged primarily by finance and banking stocks.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 11, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS